Kura Oncology KURA Unrealized gains (losses) on available-for-sale securities

Unrealized gains (losses) on available-for-sale securities at other companies

Corvus PharmaceuticalsCRVS

-$334K-1,352%

Cullinan Therapeutics, Inc.CGEM

-$893K-240%

Bicara TherapeuticsBCAX

-$486K—

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's unrealized gains (losses) on available-for-sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's unrealized gains (losses) on available-for-sale securities?: Kura Oncology (KURA) reported unrealized gains (losses) on available-for-sale securities of -$1.4M in Q1 2026.
How has Kura Oncology's unrealized gains (losses) on available-for-sale securities changed year-over-year?: Kura Oncology's unrealized gains (losses) on available-for-sale securities decreased by 768.6% year-over-year, from $210K to -$1.4M.